| In millions, except per share items | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| PDT Drug & Device Product Revenues | | | | 23.9 | 18.3 | 16.1 | 11.3 | 8.0 |
| Non-PDT Drug Product Revenues | | | | 5.6 | 9.4 | 9.5 | | |
| Other | | | | 0.7 | 0.6 | 0.8 | 1.4 | 1.6 |
| Total revenues | 45.3 | 36.4 | 28.3 | 30.2 | 28.2 | 26.4 | 12.7 | 9.6 |
| Revenue growth [+] | 24.4% | 28.5% | -6.2% | 7.1% | 6.8% | 107.6% | 33.0% | 886.2% |
| PDT Drug & Device Product Revenues | | | | 30.9% | 13.5% | 42.0% | 41.9% | |
| Non-PDT Drug Product Revenues | | | | -40.2% | -1.0% | | | |
| Cost of goods sold | 6.9 | 6.4 | 6.0 | 30.2 | 8.4 | 27.0 | 7.6 | 5.5 |
| Gross profit | 38.4 | 30.0 | 22.3 | 0.0 | 19.8 | -0.5 | 5.1 | 4.1 |
| Gross margin | 84.7% | 82.4% | 78.8% | 0.2% | 70.3% | -2.0% | 40.3% | 43.0% |
| Selling, general and administrative [+] | 25.3 | 22.3 | 20.9 | 22.3 | 23.6 | 23.8 | 15.8 | 14.8 |
| Sales and marketing | 15.4 | 13.2 | 12.9 | 13.1 | 13.3 | 12.6 | 9.1 | 7.6 |
| General and administrative | 10.0 | 9.1 | 8.0 | 9.2 | 10.3 | 11.2 | 6.7 | 7.2 |
| Research and development | 5.3 | 4.9 | 4.3 | 6.6 | 6.0 | 6.2 | 5.6 | 6.5 |
| Other operating expenses | | | | -22.7 | -0.6 | -15.7 | | |
| EBITDA [+] | 8.2 | 3.1 | -2.4 | -5.7 | -8.5 | -10.9 | -15.3 | -15.9 |
| EBITDA growth | 162.9% | -231.1% | -58.0% | -33.4% | -22.1% | -28.6% | -3.8% | 5.1% |
| EBITDA margin | 18.1% | 8.6% | -8.4% | -18.8% | -30.2% | -41.4% | -120.3% | -166.3% |
| Depreciation and amortization | 0.4 | 0.4 | 0.5 | 0.6 | 0.7 | 3.9 | 0.9 | 1.3 |
| EBIT [+] | 7.8 | 2.7 | -2.8 | -6.2 | -9.2 | -14.8 | -16.2 | -17.2 |
| EBIT growth | 184.5% | -196.2% | -54.6% | -32.1% | -38.1% | -8.6% | -5.7% | 2.7% |
| EBIT margin | 17.1% | 7.5% | -10.0% | -20.7% | -32.5% | -56.2% | -127.6% | -179.9% |
| Non-recurring items [+] | | | | 1.5 | 6.8 | 17.3 | 0.2 | |
| Asset impairment | | | | 1.5 | 6.8 | 15.7 | | |
| Other income (expense), net [+] | -1.0 | -0.2 | -0.1 | 7.7 | 1.2 | 0.8 | 1.4 | 1.6 |
| Unrealized gain/loss on derivatives | -1.0 | -0.4 | -0.4 | | | | | |
| Other | 0.0 | 0.2 | 0.3 | | | | | |
| Pre-tax income | 6.8 | 2.6 | -2.9 | 0.0 | -14.7 | -31.3 | -15.0 | -15.6 |
| Income taxes | -0.5 | -0.1 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | 5.6% | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 7.3 | 2.7 | -2.5 | 0.0 | -14.7 | -31.3 | -15.0 | -15.6 |
| Net margin | 16.2% | 7.4% | -8.9% | 0.0% | -52.1% | -118.7% | -117.9% | -163.4% |
| |
| Basic EPS [+] | $0.28 | $0.11 | ($0.11) | $0.00 | ($0.73) | ($1.65) | ($0.89) | ($0.96) |
| Growth | 161.3% | -192.6% | | -100.0% | -56.0% | 86.2% | -7.5% | |
| Diluted EPS [+] | $0.26 | $0.10 | ($0.11) | $0.00 | ($0.73) | ($1.65) | ($0.89) | ($0.96) |
| Growth | 149.1% | -190.5% | | -100.0% | -56.0% | 86.2% | -7.5% | |
| |
| Shares outstanding (basic) [+] | 24.5 | 24.2 | 24.1 | 24.1 | 20.3 | 19.0 | 16.9 | 16.3 |
| Growth | 1.4% | 0.4% | 0.1% | 18.7% | 6.8% | 12.3% | 3.8% | 17.1% |
| Shares outstanding (diluted) [+] | 26.4 | 24.8 | 24.1 | 24.1 | 20.3 | 19.0 | 16.9 | 16.3 |
| Growth | 6.4% | 2.6% | 0.2% | 18.7% | 6.8% | 12.3% | 3.8% | 17.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |